Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Neurological Research|June 23, 2024
Real-world experiences of migraine patients on Erenumab: a Kuwait single center cohortJasem Youssef Al-Hashel, Raed Alroughani, Fatemah Alshaf, et al.
Frontiers in Neurology|September 9, 2020
Demographics, Clinical Characteristics, and Management of Idiopathic Intracranial Hypertension in Kuwait: A Single-Center ExperienceJasem Youssef Al-Hashel, Ismail Ibrahim Ismail, Mohamed Ibrahim, et al.
Neurology and Therapy|June 22, 2020
Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf RegionRaed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, et al.
Frontiers in Neurology|February 15, 2021
Onabotulinumtoxin A Improves Psychological Aspects in Chronic Migraine PatientsJasem Youssef Al-Hashel, Hasan Kh Ashkanani, Ohood Almutairi, et al.
Neurology and Therapy|June 17, 2021
Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19Jihad Inshasi, Raed Alroughani, Abdullah Al-Asmi, et al.
Neurology and Therapy|June 22, 2021
Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19Jihad Inshasi, Raed Alroughani, Abdullah Al-Asmi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 14, 2022
Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative reviewRaed Alroughani, Jihad Inshasi, Mona Al Khawajah, et al.
Clinical Neurology and Neurosurgery|March 14, 2021
Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA)Raed Alroughani, Zuhair AlKawi, Ahmed Hassan, et al.
Multiple Sclerosis and Related Disorders|August 9, 2024
Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based studyMaya Zeineddine, Amal Al-Hajje, Pascale Salameh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Pageof 5